Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Items 501–600 of 608
Orlev, Y., Yahalom, G., Cohen, O. S., Elincx-Benizri, S., Kozlova, E., Inzelberg, R., Goldbourt, U., & Hassin‐Baer, S. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.10.009 · Cited by 2
α-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease
Altarescu, G., Ioscovich, D., Alcalay, R. N., Zimran, A., & Elstein, D. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.07.051 · Cited by 2
Usenko, T. S., Bezrukova, A. I., Bogdanova, D., Nikolaev, M. A., Miliukhina, I. V., Gracheva, E., Senkevich, K. A., Zakharova, E. Y., Emelyanov, A., & Pchelina, S. (2020) · Annals of Clinical and Experimental Neurology · doi:10.25692/acen.2020.2.6 · Cited by 2
Bonifati, V. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.007 · Cited by 2
Genetic Testing for GBA and LRRK2 Mutations: Is it Time for Routine Use?
Roopnarain, K., & Klein, C. (2022) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13619 · Cited by 2
“Pathogenic GBA variants have been identified in various populations but are most frequently detected among people of Ashkenazi Jewish descent.(8) LRKK2 and GBA mutations bridge the etiological gap between sporadic and hereditary PD, being both risk and causal factors to variable degrees on a continuum of reduced penet…”
BackgroundFACTORES GENÉTICOS INVOLUCRADOS EN LA SUSCEPTIBILIDAD PARA DESARROLLAR ENFERMEDAD DE PARKINSON
Morgado, H. V., Vilatela, M. E. A., & López, M. (2004) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 2
Etiopathogenesis of vitiligo in the light of our studies.
Chorazak, T., & Rzempołuch, E. (1968) · PubMed · Cited by 2
Head injury, pathophysiology and management, second edition
Grieve, J. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.071902 · Cited by 2
Neuropathology and staging of parkinson’s disease
Dickson, D. W. (2007) · Cited by 2
Zokaei, N. (2013) · UCL Discovery (University College London) · Cited by 2
Long-read transcriptomics in neurodegeneration
Gustavsson, E. K., & Macpherson, H. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13550-7.00002-1 · Cited by 1
Elucidating Pathological Mechanisms and Developing Biomarkers of Parkinson's Disease
Hatano, T. (2025) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.70013 · Cited by 1
Mizutani, Y., Nawashiro, K., Ito, S., NAKAI, T., Ohdake, R., Shima, S., Ueda, A., Ito, M., Mutoh, T., & Watanabe, H. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107151 · Cited by 2
GBA1 Gene-Associated Transcriptomic Signatures Reveal Risk Genes in Parkinson’s Disease
Liu, Y., Luo, X., & Fleming, R. M. T. (2025) · Biomedicines · doi:10.3390/biomedicines13112799 · Cited by 2
Clinician and patient perspectives on meaningful Parkinson's disease impacts for digital assessment
Pearlmutter, A., Ellis, R., & Peterschmitt, M. J. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1677680 · Cited by 1
Kraus, F., He, Y., Jiang, Y., Li, D., Ambaw, Y. A., Gasparoli, F. M., Paulo, J. A., Walther, T. C., Farese, R. V., Gygi, S. P., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2609132123 · Cited by 1
GBA1 in Parkinson’s disease: past, present and future
Gan‐Or, Z. (2026) · Brain · doi:10.1093/brain/awag322 · Cited by 1
Niethammer, M., & Franceschi, A. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_36 · Cited by 1
Neuronopathic Forms in Subjects with Mutations in GBA Gene
Giraldo, P., Capablo, J.-L., & Pocoví, M. (2011) · InTech eBooks · doi:10.5772/18949 · Cited by 1
“In a clinic-based series of Parkinson disease patients from Israel, (Aharon-Peretz et al., 2004) screened for the most frequent mutations in glucocerebrosidase gene, they identified 31% with glucocerebrosidase mutations including three N370S homozygotes.”
BackgroundIdentifying the genetic components underlying the pathophysiology of movement disorders
Martí, M. J., Ezquerra, M., & Compta (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s7333 · Cited by 1
Mamais, A., & Cookson, M. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00042-8 · Cited by 1
Mutational analysis of a cohort of Egyptian patients with Gaucher disease
Fateen, E., Fathy, H. M., Maaty, D. M. A., Kamel, N. M., & Aleem, A. K. A. (2017) · Middle East Journal of Medical Genetics · doi:10.1097/01.mxe.0000520527.54080.ab · Cited by 1
Parkinson’s Disease, Lithium and Stem Cells
Burckhalter, L., & Gallicchio, V. S. (2019) · Journal of Clinical and Laboratory Medicine · doi:10.16966/2572-9578.126 · Cited by 1
“This gene and its associated mutations are more commonly known for causing Gaucher’s disease, and GBA mutations are common in AshkenaziJews [26].”
BackgroundParkinson’s disease and the spectrum of Lewy body disease
Barone, P., Pellecchia, M. T., & Amboni, M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511920936.003 · Cited by 1
Gruschus, J. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85707-9.00012-5 · Cited by 1
Identification of potential Parkinson’s disease biomarkers using computational biology approaches
Chowdhury, H. A., Barah, P., Bhattacharyya, D. K., & Kalita, J. K. (2021) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-020-00280-5 · Cited by 1
Khwanraj, K., Choubtum, L., Taweewongsounton, A., Tanrattanakorn, S., Pulkes, T., & Dharmasaroja, P. (2016) · Journal of Neurology Research · doi:10.14740/jnr375w · Cited by 1
Han, N., Paul, R., Bardakjian, T., Kargilis, D., Bradbury, A. R., Chen‐Plotkin, A. S., & Tropea, T. F. (2023) · JMIR Bioinformatics and Biotechnology · doi:10.2196/45370 · Cited by 1
“Variants in leucine-rich repeat kinase 2 (LRRK2), glucocerebrosidase (GBA), Parkin, Parkinsonism-associated deglycase (DJ-1), VPS35 retromer complex component (VPS35), PTEN-induced kinase 1 (PINK1), and α-synuclein (SNCA) are identified in 10%-12% of PD cases [3-9].”
BackgroundClinical prediction of GBA carrier status in Parkinson’s disease
Greenberg, J. H., Astudillo, K., Frucht, S. J., Flinker, A., & Riboldi, G. M. (2024) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2024.100251 · Cited by 1
“…variants of GBA in the study cohort (N409S in 13 subjects, R535H in 1 subject, L29Afs*18 in 1 subject, H294Q in 1 subject), 1 established PD risk variant (E365K in 4 subjects), and 2 variants of unknown significance or likely pathogenic (Q182 = in 1 subject, W387G in 1 subject) [2,5,16,18].”
BackgroundMethodResultTrojanowski, J. Q., Forman, M. S., & Lee, V. M. ‐. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_13 · Cited by 1
“Finally, although it was well known that heterozygous mutations in the glucocerebrosidase gene (GBA) cause autosomal recessive Gaucher’s disease, recent studies identified heterozygous mutations in the GBA gene that increase the risk for LB PD. They also showed that patients who present with Gaucher’s disease often de…”
BackgroundLRRK2 genetics and expression in the Parkinsonian brain
Sharma, S. (2010) · UCL Discovery (University College London) · Cited by 1
Giraldo, P., & Pocoví, M. (2008) · Medicina Clínica · doi:10.1157/13116550 · Cited by 1
Tetrahydroisoquinoline Neurotoxins in Parkinson Disease
DeCuypere, M. G. (2010) · doi:10.21007/etd.cghs.2010.0067 · Cited by 2
“The majority of LBs in SNpc neurons exhibit a loose, radiating array of filaments in the periphery of the LB, surrounding a matted meshwork of filaments in the center or core (Forno 1996; Hill et al 1991; Pollanen et al 1993; Schmidt et al 1991).”
BackgroundInfluentialGenetic Models of Parkinson’s Disease
Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1
Current Concepts on the Etiology and Pathogenesis of Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50008-5 · Cited by 2
Tropea, T. F., Hartstone, W. G., Amari, N., Baum, D., Rick, J. H., Suh, E. R., Zhang, H., Paul, R., Han, N., Zack, R., et al. (2024) · Research Square · doi:10.21203/rs.3.pex-2505/v1 · Cited by 1
Rôle des sphingolipides dans la cancérogenèse : l'exemple de la maladie de Gaucher
Astudillo, L. M. (2016) · theses.fr (ABES) · doi:10.70675/fa7a5078z1170z48a0z81a7z05c9d8e7a135 · Cited by 1
The genetic architecture of Parkinson's disease : emphasis on genetic susceptibility
Brás, J. (2010) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Genetic Basis of Monogenic Forms of Parkinson Disease
Brockmann, K., & Gasser, T. (2010) · Wiley eBooks · doi:10.1002/9780470015902.a0022397
Harbo, H. F., Finsterer, J., Baets, J., Broeckhoven, C. V., Donato, S. D., Fontaine, B., Jonghe, P. D., Lossos, A., Lynch, T., Mariotti, C., et al. (2011) · Wiley eBooks · doi:10.1002/9781444346268.ch4
Mutações da glicocerebrosidade em pacientes com doença de Parkinson
Spitz, M. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2006.tde-05022007-123329
Filterable Forms of Nocardia: An Infectious Focus in the Parkinsonian Midbrains
Kohbata, S., Hayashi, R., Tamura, T., & Kadoy, C. (2012) · InTech eBooks · doi:10.5772/16761
“Mutations in the glucocerebrosidase genes encoding lysosomal enzymes emerge as strong genetic determinants predisposing people to PD (Aharon-Peretz et al., 2004).”
BackgroundRole of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease
Beccari, T., Balducci, C., Paciotti, S., Persichetti, E., Chiasserini, D., Castrioto, A., Tambasco, N., Rossi, A., Calabresi, P., Pagliardini, V., et al. (2011) · InTech eBooks · doi:10.5772/23552 · Cited by 1
“Subsequently Aharon-Peretz et al. (2004), explored the association between six GBA mutations (N370S, L444P, c.”
BackgroundInfluentialGaucher Disease: Review and Perspectives on Treatment
Cabrera-Salazar, M. A., & Barranger, J. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70909-3_21
Melamed, E. (2013) · Movement Disorders · doi:10.1002/mds.25728
“As if this is not enough, it was found that mutations in the glucocerebrosidase (GBA) gene that cause Gaucher’s disease in Ashkenazi Jews, also act as a susceptibility gene, increasing the risk of developing Parkinson’s disease manifold.(11,12) After so many years of research, it is still unknown”
Background"Análise molecular das doenças de Gaucher e Tay-Sachs no Brasil"
Rozenberg, R. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2006.tde-27092006-154138 · Cited by 1
Basi molecolari del morbo di Parkinson
Lesage, S., & Brice, A. (2010) · EMC - Neurologia · doi:10.1016/s1634-7072(10)70497-9
Giménez, R. Á. F. D. L. P., & Calvo, J. (2008) · Medicina Clínica · doi:10.1157/13127923
Várkonyi, J., Molnar, M. Z., Kovács, M., & Prohászka, Z. (2007) · Hungarian Medical Journal · doi:10.1556/hmj.1.2007.3.10
International Study Confirms Glucocerebrosidase Mutations in Parkinson Disease
Samson, K. (2009) · Neurology Today · doi:10.1097/01.nt.0000365668.16401.d1
Aspects neurologiques de la maladie de Gaucher
Hartmann, A. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74949-1
Studies of Glucocerebrosidase Provide New Therapeutic Targets For Parkinsonism
Kim, J., Lopez, G. J., & Sidransky, E. (2014) · Future Neurology · doi:10.2217/fnl.14.37
Neurological aspects of Gaucher and Fabry disease
Biegstraaten, M. (2011) · UvA-DARE (University of Amsterdam)
Singh, P. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-2936
“Among the high-risk Ashkenazi Jewish subset of ethnic groups, GBA1 mutations were present in 31.3% of patients with idiopathic PD (Aharon-Peretz et al., 2004).”
BackgroundInfluentialLi, C. (2013) · Digital Repository Service (Northeastern University) · doi:10.17760/d20003206
The Many Faces of Parkinsonism: A Review of the Parkinson Look-alike Syndromes
Schneider, S. A., & Klein, C. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199609536.003.0012
Parkinson’s Disease: Premotor Features, Diagnosis, and Early Management
Schapira, A. H. V., & Gallagher, D. A. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199609536.003.0009
5 Stem Cells for Parkinson’s Disease
Lamba, D. A. (2017) · CRC Press eBooks · doi:10.1201/9781315402185-6
Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease
Fletcher, E. J. R. (2017) · Research Portal (King's College London)
Alpha-Synuclein and synuceinopathies as related to Parkinson's disease
Anyanwu, F. E. (2017) · BIBSYS Brage (BIBSYS (Norway))
Relationship between Gaucher disease and parkinsonism
Johal, K. J., Lopez, G. J., & Sidransky, E. (2013) · doi:10.2217/ebo.12.253
Basi molecolari della malattia di Parkinson
Monin, M., Lesage, S., & Brice, A. (2019) · EMC - Neurologia · doi:10.1016/s1634-7072(18)41584-x
Some genetic factors of Parkinson’s disease in the Hungarian population
Maszlag-Török, R. (2018) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.9951
Lee, H. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-vmrpwo829
Evaluating Digital Health Technologies to Advance Parkinson's Disease Care
Dominey, T. (2019) · PEARL (University of Plymouth) · doi:10.24382/770 · Cited by 1
Rosenberg, A. E., & Giladi, N. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00326-9 · Cited by 1
Mechanisms of Olfactory Deficits in Parkinson's Disease
Chandra, S. S., & Greer, C. A. (2018)
Parkinson's disease: Genetic-driven therapeutic approaches
Sardi, S. P., & Baptista, M. A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00008-2
de Araújo, F. T. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2020.tde-15062020-162144
α-Synuclein Aggregation and Propagation in the Pathomechanisms of Parkinson’s Disease
Hatano, T. (2021) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.jmj21-0029-r
Niemann–Pick disease type B and Parkinson’s disease: a coexistence or an etiological association?
Önder, H., Koçer, B., Düzkale, N., & Çomoǧlu, S. (2022) · Neurological Sciences · doi:10.1007/s10072-021-05860-5
“The lysosomal dysfunction has been linked with PD and the patients with Gaucher’s disease, the most common lysosomal storage disorder, are shown to be at significantly increased risk for developing PD, with an earlier age of onset [4].”
BackgroundKavanagh, P., & Marder, K. S. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-429-6_4
Gaucher disease and Lupus: A rare association?
Jerónimo, T. M., Cabrita, A., Pimentel, A., Vidinha, J., Fragoso, A., Santos, V., Bernardo, I., Viana, H., Carvalho, F., Brito, H. L., et al. (2016) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2016.05.008
BMJ Publishing Group Ltd (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.073239corr1
Parkinsons Disease: Recent Advancement and Future Aspects
Indrakshi, T., Aparna, A., Krishna, H., Aashul, N., & Rajawat, J. S. (2022) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2022.47171
Anlaş, Ö. (2022) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2022.12.000781
(2023) · Advances in magnetic resonance technology and applications · doi:10.1016/b978-0-323-91771-1.00018-6
Gaucher’s disease is a common storage disorder but rare entity: Two case report
Verma, K. K., & Hussain, N. (2023) · IP Journal of diagnostic pathology and oncology/IP journal of diagnostic pathology and oncology/Journal of diagnostic pathology and oncology · doi:10.18231/j.jdpo.2023.029
II. Advances in Genetic Medicine-Aiming to Realize Disease-Modifying Therapy in Parkinson's Disease
Hattori, N. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.1511
Parkinson's Disease: Pathophysiology, Diagnosis, and Perspectives
Brandão, P. R. D. P. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-0851-6.ch008
Ethno-Racial Background and Risk for Parkinson’s Disease
Siddiqi, S. (2022) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2022-16198
Hyperuricaemia in type 1 Gaucher disease: is uric acid a biomarker for disease severity?
Hexner‐Erlichman, Z., Watad, S., Szer, J., Habashi, N., & Rosenbaum, H. (2025) · Internal Medicine Journal · doi:10.1111/imj.70102
Self-citationΑνοσογενετικός κίνδυνος στην νόσο Πάρκινσον
Μαρογιάννη, Χ. (2025) · doi:10.12681/eadd/59241
Glucocerebrosidase Gene Mutations and Parkinsonism
Aharon‐Peretz, J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00180-5
Self-citationJiang, Z., Huang, Y., Zhang, P., Han, C., Lu, Y., Mo, Z., Zhang, Z., Li, X., Zhao, S., Cai, F., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12629769
Gabbert, C., Schaake, S., Lüth, T., Much, C., Klein, C., Aasly, J. O., Farrer, M. J., & Trinh, J. (2023) · Figshare · doi:10.6084/m9.figshare.23512772
Doença de Parkinson: genética e farmacogenómica
Damásio, M. P. C. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Romdhan, S. B. (2019) · theses.fr (ABES) · doi:10.70675/6735d8bdz3448z4836z8b6dzffcd8f2bd2da · Cited by 1
Impacts de la modulation du cholestérol cérébral dans la maladie de Parkinson
Rousselot, L. (2023) · theses.fr (ABES) · doi:10.70675/c92a8ee9zd623z4ebbz813az17685082f328
The Emerging Parkinson's Disease Oxylipin‐Ome
Kelliher, J. C., & Fanning, S. (2026) · Advanced Science · doi:10.1002/advs.202522997
Noncoding variation and regulatory control of SNCA in Lewy body dementia
Junn, E. (2026) · npj Dementia · doi:10.1038/s44400-026-00079-7
Suoranta, M., Kytövuori, L., Haataja, E., Myller, E. M., Jaakkola, E., Noponen, T., Eklund, M. R. E., Nuuttila, S., Joutsa, J., Murtomäki, K., et al. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108410
Cortical and subcortical morphological alterations in de novo GBA-related Parkinson’s disease
Ren, J., Xing, Y., Zhou, H., Hong, X., Huang, X., & Liu, W. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1885255
Guatteo, E., Romano, M. Z., Berretta, N., Ruggiero, M., Santoro, A., Mazzeo, F., & Meccariello, R. (2026) · Microplastics · doi:10.3390/microplastics5030166
Gowda, N. B., & Harish, S. (2026) · Neurogenetics · doi:10.1007/s10048-026-00946-8
“Founder mutations such as N370S and L444P are particularly common among Ashkenazi Jews, where GBA1-associated PD constitutes one of the most important genetic risk factors for the disease [ 48 ].”
Dinter, E., Szegő, É. M., Luksch, H., Höfs, L., & Falkenburger, B. H. (2026) · Research Square · doi:10.21203/rs.3.rs-11097164/v1
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.